奥瑞利珠单抗与利妥昔单抗治疗多发性硬化的真实世界安全性比较
本研究利用加州大学健康系统回顾性数据模拟目标临床试验,比较奥瑞利珠单抗与利妥昔单抗治疗多发性硬化的长期安全性。经倾向评分匹配后,利妥昔单抗组全因住院率和低丙种球蛋白血症风险均显著高于奥瑞利珠单抗组,在两个独立队列中结论一致。
要点
- 利妥昔单抗全因住院率显著高于奥瑞利珠单抗,UCSF队列IRR=2.29,UC-wide队列IRR=4.54。
- 利妥昔单抗低丙种球蛋白血症风险更高,UCSF队列HR=2.72,UC-wide队列HR=4.79。
- 奥瑞利珠单抗在住院和低丙种球蛋白血症方面显示更优安全性,可辅助治疗决策。
核心结论
- 在两个独立队列中,奥瑞利珠单抗比利妥昔单抗具有更有利的安全性,住院率和低丙种球蛋白血症发生率更低。
研究设计与样本
- 利用加州大学健康系统回顾性数据模拟目标临床试验,主要队列来自UCSF,验证队列来自其他5个UC医学中心。
- 经排除标准和基于疾病特征、人口学及社会经济因素的倾向评分匹配后,比较奥瑞利珠单抗与利妥昔单抗治疗的多发性硬化患者。
- UCSF队列中奥瑞利珠单抗n=542、利妥昔单抗n=271;UC-wide验证队列中分别为n=486和n=162。
主要发现
- 利妥昔单抗全因住院率高于奥瑞利珠单抗:UCSF队列IRR=2.29(95%CI 1.37-3.82,p=0.001),UC-wide队列IRR=4.54(95%CI 4.30-7.61,p<0.001)。
- 利妥昔单抗累积风险比同样升高:UCSF队列HR=2.27(95%CI 1.37-3.75,p=0.001),UC-wide队列HR=4.01(95%CI 2.25-6.32,p<0.001)。
- 利妥昔单抗低丙种球蛋白血症风险更高:UCSF队列HR=2.72(95%CI 1.18-6.29,p=0.003),UC-wide队列HR=4.79(95%CI 2.04-11.25,p<0.001)。
临床怎么用
- 对于多发性硬化患者,选择B细胞耗竭治疗时可将住院和低丙种球蛋白血症风险纳入考量,奥瑞利珠单抗在这两方面安全性更优。
局限性
- 本研究为回顾性观察性研究,虽采用倾向评分匹配模拟目标临床试验,但仍可能存在未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to compare the long-term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). METHODS: Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from 5 other UC Medical Centers were analyzed. After applying exclusion criteria and propensity score matching based on disease characteristics, demographics, and socioeconomic factors, we compared UCSF patients receiving ocrelizumab (n = 542) and rituximab (n = 271)and validated in the UC-wide MS population (n = 486 and n = 162 patients, respectively). The primary outcome was an all-cause hospitalization rate; secondary outcomes included hypogammaglobulinemia development and infection incidence. RESULTS: Rituximab showed higher all-cause hospitalization rates compared to ocrelizumab in both UCSF (incidence rate ratio [IRR] = 2.29, 95% confidence interval [CI] = 1.37-3.82, p = 0.001) and UC-wide cohorts (IRR = 4.54, 95% CI = 4.30-7.61, p < 0.001). Cumulative hazard ratios (HRs) were similarly elevated with rituximab at UCSF (HR = 2.27, 95% CI = 1.37-3.75, p = 0.001) and UC-wide (HR = 4.01, 95% CI = 2.25-6.32, p < 0.001). The risk of developing hypogammaglobulinemia was higher with rituximab at both UCSF (HR = 2.72, 95% CI = 1.18-6.29, p = 0.003) and UC-wide (HR = 4.79, 95% CI = 2.04-11.25, p < 0.001). INTERPRETATION: A more favorable safety profile was observed for ocrelizumab, with lower rates of hospitalization and hypogammaglobulinemia across 2 independent cohorts. These findings may help guide treatment strategies in persons with MS. ANN NEUROL 2026;99:248-260.
引用
- Cerono G, Cree BAC, Hauser SL, et al. Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence. Ann Neurol. 2025. PMID: 40919837. doi:10.1002/ana.78033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。